Journal: Nature reviews. Urology
This review highlights the twentieth anniversary of FDA approval of docetaxel for advanced prostate cancer, marking a significant advancement as the first non-antiandrogen therapy to improve survival.
It summarizes current evidence supporting taxane use, including its combination with androgen-targeting therapies in early-stage metastatic hormone-sensitive prostate cancer, establishing taxanes as a treatment gold standard.
The article also explores the mechanisms underlying taxane effectiveness and resistance, offering insights into how resistance pathways could be targeted to enhance future therapeutic strategies.